The U.S. oncology market, valued at $81.34 billion in 2025, is projected to reach $211.78 billion by 2034, growing at a CAGR of 11.75%, according to a report by Towards Healthcare, a healthcare and life science research & business consulting firm. There have been many therapeutic advancements in oncology, from chemotherapy to tyrosine kinase inhibitors and monoclonal antibodies. The top-selling cancer drug, Keytruda, developed by Merck, is a monoclonal antibody.
The company we are profiling today is Bicycle Therapeutics plc (BCYC), which is developing drugs with the potential to be the next major transformative solution in oncology.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com